The CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY): design of a Phase III trial of oral cladribine in relapsing multiple sclerosis

被引：0
|
作者：
Giovannoni, G.
Comi, G.
Cook, S.
Beelke, M.
Rieckmann, P.
Sorensen, P. S.
Vermersch, P.
机构：
来源：
MULTIPLE SCLEROSIS | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S245 / S245
页数：1
相关论文
共 50 条
  • [31] Expert opinion consensus on recommendations for treating relapsing multiple sclerosis with cladribine tablets in daily clinical practice
    Sorensen, P. Soelberg
    Centonze, D.
    Giovannoni, G.
    Montalban, X.
    Selchen, D.
    Vermersch, P.
    Wiendl, H.
    Yamout, B.
    Salloukh, H.
    Rieckmann, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 945 - 946
  • [32] Durability of NEDA-3 status in patients with relapsing multiple sclerosis receiving cladribine tablets: CLARITY Extension
    Giovannoni, Gavin
    Keller, Birgit
    Jack, Dominic
    NEUROLOGY, 2019, 92 (15)
  • [33] Effectiveness Of Cladribine Tablets In Patients With Relapsing-remitting Multiple Sclerosis With Baseline EDSS ≥3.5 Or ≤3.0 In CLARITY
    Comi, G.
    Pardo, G.
    Dangond, F.
    Aldridge, J.
    Lemieux, C.
    Rammohan, K.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 42 - 43
  • [34] Real-World Outcomes With Cladribine Tablets in People With Relapsing Multiple Sclerosis
    Okuda, Darin
    Livingston, Terrie
    Moog, Tatum
    Smith, Alexander
    Lebson, Lori
    Piette, Elizabeth
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1100 - 1100
  • [35] Durability of NEDA-3 Status in Patients with Relapsing Multiple Sclerosis Receiving Cladribine Tablets: CLARITY Extension
    Giovannoni, Gavin
    Keller, Birgit
    Jack, Dominic
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 47 - 48
  • [36] Cladribine Tablets Demonstrate Similar Efficacy In Male And Female Patients With Relapsing-remitting Multiple Sclerosis In CLARITY
    Pardo, G.
    Dangond, F.
    Aldridge, J.
    Lemieux, C.
    Bowen, J. D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 40 - 40
  • [37] Durability of NEDA-3 Status in Patients with Relapsing Multiple Sclerosis Receiving Cladribine Tablets: CLARITY Extension
    Giovannoni, G.
    Keller, B.
    Jack, D.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 467 - 467
  • [38] Real world experience with cladribine tablets in the management of relapsing multiple sclerosis in Qatar
    Canibano, Beatriz Garcia
    Okar, Lina
    Baniamer, Yahya Zakarya
    Deleu, Dirk
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2024, 247
  • [39] Durability of NEDA-3 status in patients with relapsing multiple sclerosis receiving cladribine tablets: CLARITY extension
    Giovannoni, G.
    Keller, B.
    Jack, D.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 479 - 480
  • [40] Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
    Clavelou, Pierre
    Castelnovo, Giovanni
    Pourcher, Valerie
    De Seze, Jerome
    Vermersch, Patrick
    Ben-Amor, Ali-Frederic
    Savarin, Carine
    Defer, Gilles
    NEUROLOGY AND THERAPY, 2023, 12 (05) : 1457 - 1476
12345